Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Index by author

December 01, 1985; Volume 28,Issue 6
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Abrass, I B

    1. You have access
      Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;
  2. Akaike, A

    1. You have access
      The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;
  3. Albuquerque, E X

    1. You have access
      The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;
  4. Aracava, Y

    1. You have access
      The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;
  5. Autry, W L

    1. You have access
      Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.
      J A Norman, W L Autry and B S Barbaz
      Molecular Pharmacology December 1985, 28 (6) 521-526;
  6. Ayusawa, D

    1. You have access
      Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

B

  1. Balzarini, J

    1. You have access
      Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;
  2. Barbaz, B S

    1. You have access
      Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.
      J A Norman, W L Autry and B S Barbaz
      Molecular Pharmacology December 1985, 28 (6) 521-526;
  3. Baresi, L A

    1. You have access
      Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;
  4. Barovsky, K

    1. You have access
      Forskolin potentiation of cholera toxin-stimulated cyclic AMP accumulation in intact C6-2B cells. Evidence for enhanced Gs-C coupling.
      K Barovsky and G Brooker
      Molecular Pharmacology December 1985, 28 (6) 502-507;
  5. Battaglia, G

    1. You have access
      [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
      A B Norman, G Battaglia and I Creese
      Molecular Pharmacology December 1985, 28 (6) 487-494;
  6. Blumer, J L

    1. You have access
      Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;
  7. Borgeat, P

    1. You have access
      Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.
      H Salari, P Braquet and P Borgeat
      Molecular Pharmacology December 1985, 28 (6) 546-548;
  8. Braquet, P

    1. You have access
      Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.
      H Salari, P Braquet and P Borgeat
      Molecular Pharmacology December 1985, 28 (6) 546-548;
  9. Bräutigam, M

    1. You have access
      Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.
      M Bräutigam, B Kittner and G Laschinski
      Molecular Pharmacology December 1985, 28 (6) 515-520;
  10. Brimijoin, S

    1. You have access
      An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme.
      S Brimijoin, K P Mintz and F G Prendergast
      Molecular Pharmacology December 1985, 28 (6) 539-545;
  11. Brooker, G

    1. You have access
      Forskolin potentiation of cholera toxin-stimulated cyclic AMP accumulation in intact C6-2B cells. Evidence for enhanced Gs-C coupling.
      K Barovsky and G Brooker
      Molecular Pharmacology December 1985, 28 (6) 502-507;
  12. Bürgisser, E

    1. You have access
      Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;

C

  1. Creese, I

    1. You have access
      [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
      A B Norman, G Battaglia and I Creese
      Molecular Pharmacology December 1985, 28 (6) 487-494;

D

  1. Daly, J W

    1. You have access
      The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;
  2. De Clercq, E

    1. You have access
      Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

E

  1. Erne, P

    1. You have access
      Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;
  2. Evans, H H

    1. You have access
      Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;

F

  1. Ferracin, F

    1. You have access
      Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;

G

  1. Giedroc, D P

    1. You have access
      Binding of a synthetic beta-endorphin peptide to calmodulin.
      D P Giedroc and D Puett
      Molecular Pharmacology December 1985, 28 (6) 588-593;

H

  1. Handwerger, S

    1. You have access
      Arachidonic acid stimulates phosphoinositide hydrolysis and human placental lactogen release in an enriched fraction of placental cells.
      P Zeitler and S Handwerger
      Molecular Pharmacology December 1985, 28 (6) 549-554;

K

  1. Kittner, B

    1. You have access
      Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.
      M Bräutigam, B Kittner and G Laschinski
      Molecular Pharmacology December 1985, 28 (6) 515-520;

L

  1. Laschinski, G

    1. You have access
      Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomes.
      M Bräutigam, B Kittner and G Laschinski
      Molecular Pharmacology December 1985, 28 (6) 515-520;
  2. Laufen, H

    1. You have access
      The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.
      R A Yeates, H Laufen and M Leitold
      Molecular Pharmacology December 1985, 28 (6) 555-559;
  3. Leitold, M

    1. You have access
      The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.
      R A Yeates, H Laufen and M Leitold
      Molecular Pharmacology December 1985, 28 (6) 555-559;

M

  1. Malick, N C

    1. You have access
      Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
      R D Snyder and N C Malick
      Molecular Pharmacology December 1985, 28 (6) 574-580;
  2. Mintz, K P

    1. You have access
      An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme.
      S Brimijoin, K P Mintz and F G Prendergast
      Molecular Pharmacology December 1985, 28 (6) 539-545;

N

  1. Norman, A B

    1. You have access
      [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
      A B Norman, G Battaglia and I Creese
      Molecular Pharmacology December 1985, 28 (6) 487-494;
  2. Norman, J A

    1. You have access
      Angiotensin-converting enzyme inhibitors potentiate the analgesic activity of [Met]-enkephalin-Arg6-Phe7 by inhibiting its degradation in mouse brain.
      J A Norman, W L Autry and B S Barbaz
      Molecular Pharmacology December 1985, 28 (6) 521-526;

P

  1. Pellack-Walker, P

    1. You have access
      Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;
  2. Pletscher, A

    1. You have access
      Activation of human blood platelets by arginine-vasopressin. Role of bivalent cations.
      A Pletscher, P Erne, E Bürgisser and F Ferracin
      Molecular Pharmacology December 1985, 28 (6) 508-514;
  3. Prendergast, F G

    1. You have access
      An inhibitory monoclonal antibody to rabbit brain acetylcholinesterase. Studies on interaction with the enzyme.
      S Brimijoin, K P Mintz and F G Prendergast
      Molecular Pharmacology December 1985, 28 (6) 539-545;
  4. Puett, D

    1. You have access
      Binding of a synthetic beta-endorphin peptide to calmodulin.
      D P Giedroc and D Puett
      Molecular Pharmacology December 1985, 28 (6) 588-593;

R

  1. Rickett, D L

    1. You have access
      The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;

S

  1. Salari, H

    1. You have access
      Stimulation of lipoxygenase product synthesis in human leukocytes and platelets by melittin.
      H Salari, P Braquet and P Borgeat
      Molecular Pharmacology December 1985, 28 (6) 546-548;
  2. Sanford, D A

    1. You have access
      Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;
  3. Sartorelli, A C

    1. You have access
      Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
      J A Sokoloski and A C Sartorelli
      Molecular Pharmacology December 1985, 28 (6) 567-573;
  4. Scarpace, P J

    1. You have access
      Desensitization and resensitization of beta-adrenergic receptors in a smooth muscle cell line.
      P J Scarpace, L A Baresi, D A Sanford and I B Abrass
      Molecular Pharmacology December 1985, 28 (6) 495-501;
  5. Seno, T

    1. You have access
      Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;
  6. Shaw, K P

    1. You have access
      The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.
      K P Shaw, Y Aracava, A Akaike, J W Daly, D L Rickett and E X Albuquerque
      Molecular Pharmacology December 1985, 28 (6) 527-538;
  7. Snyder, R D

    1. You have access
      Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
      R D Snyder and N C Malick
      Molecular Pharmacology December 1985, 28 (6) 574-580;
  8. Sokoloski, J A

    1. You have access
      Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
      J A Sokoloski and A C Sartorelli
      Molecular Pharmacology December 1985, 28 (6) 567-573;

V

  1. Verbruggen, A

    1. You have access
      Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
      J Balzarini, E De Clercq, A Verbruggen, D Ayusawa and T Seno
      Molecular Pharmacology December 1985, 28 (6) 581-587;

W

  1. Walker, J K

    1. You have access
      Relationship between the oxidation potential of benzene metabolites and their inhibitory effect on DNA synthesis in L5178YS cells.
      P Pellack-Walker, J K Walker, H H Evans and J L Blumer
      Molecular Pharmacology December 1985, 28 (6) 560-566;

Y

  1. Yeates, R A

    1. You have access
      The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.
      R A Yeates, H Laufen and M Leitold
      Molecular Pharmacology December 1985, 28 (6) 555-559;

Z

  1. Zeitler, P

    1. You have access
      Arachidonic acid stimulates phosphoinositide hydrolysis and human placental lactogen release in an enriched fraction of placental cells.
      P Zeitler and S Handwerger
      Molecular Pharmacology December 1985, 28 (6) 549-554;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 28, Issue 6
1 Dec 1985
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics